Premium
Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Author(s) -
Khattri Saakshi,
Brunner Patrick M.,
Garcet Sandra,
Finney Robert,
Cohen Steven R.,
Oliva Margeaux,
Dutt Riana,
FuentesDuculan Judilyn,
Zheng Xiuzhong,
Li Xuan,
Bonifacio Kathleen M.,
Kunjravia Norma,
Coats Israel,
Cueto Inna,
Gilleaudeau Patricia,
SullivanWhalen Mary,
SuárezFariñas Mayte,
Krueger James G.,
GuttmanYassky Emma
Publication year - 2017
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13112
Subject(s) - ustekinumab , medicine , atopic dermatitis , scorad , placebo , psoriasis , adverse effect , clinical endpoint , dermatology , randomized controlled trial , gastroenterology , disease , infliximab , pathology , dermatology life quality index , alternative medicine
Atopic dermatitis ( AD ) is the most common inflammatory skin disease, but treatment options for moderate‐to‐severe disease are limited. Ustekinumab is an IL ‐12/ IL ‐23p40 antagonist that suppresses T h1, T h17 and T h22 activation, commonly used for psoriasis patients. We sought to assess efficacy and safety of ustekinumab in patients with moderate‐to‐severe AD . In this phase II , double‐blind, placebo‐controlled study, 33 patients with moderate‐to‐severe AD were randomly assigned to either ustekinumab (n=16) or placebo (n=17), with subsequent crossover at 16 weeks, and last dose at 32 weeks. Background therapy with mild topical steroids was allowed to promote retention. Study endpoints included clinical ( SCORAD 50) and biopsy‐based measures of tissue structure and inflammation, using protein and gene expression studies. The ustekinumab group achieved higher SCORAD 50 responses at 12, 16 (the primary endpoint) and 20 weeks compared to placebo, but the difference between groups was not significant. The AD molecular profile/transcriptome showed early robust gene modulation, with sustained further improvements until 32 weeks in the initial ustekinumab group. Distinct and more robust modulation of T h1, T h17 and T h22 but also T h2‐related AD genes was seen after 4 weeks of ustekinumab treatment (i.e. MMP 12, IL ‐22, IL ‐13, IFN ‐γ, elafin/ PI 3, CXCL 1 and CCL 17; P <.05). Epidermal responses ( K 16, terminal differentiation) showed faster (4 weeks) and long‐term regulation (32 weeks) from baseline in the ustekinumab group. No severe adverse events were observed. Ustekinumab had clear clinical and molecular effects, but clinical outcomes might have been obscured by a profound “placebo” effect, most likely due to background topical glucocorticosteroids and possibly insufficient dosing for AD .